<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Sex cord-stromal tumors of the ovary: Management in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Sex cord-stromal tumors of the ovary: Management in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Sex cord-stromal tumors of the ovary: Management in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David M Gershenson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Barbara Goff, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rochelle L Garcia, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Don S Dizon, MD, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alana Chakrabarti, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sadhna R Vora, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 29, 2021.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H694430300">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ovarian sex cord-stromal tumors (SCSTs)  (
         <a class="graphic graphic_table graphicRef77703" href="/z/d/graphic/77703.html" rel="external">
          table 1
         </a>
         ) are a group of benign and malignant neoplasms that develop from the sex cord (eg, Sertoli cell tumor, granulosa cell tumor), stromal cells (eg, fibroma, thecoma, Leydig cell tumor), or both (eg, Sertoli-Leydig cell tumor). They may be benign or malignant. In contrast to the more common epithelial ovarian cancer, malignant SCSTs are often diagnosed at an early stage, histology is generally low grade, lymph node metastases are rare, and prognosis is good.
        </p>
        <p>
         This topic will discuss the management and follow-up of patients with ovarian SCSTs. The epidemiology, clinical features, and diagnosis of ovarian SCSTs are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/16833.html" rel="external">
          "Sex cord-stromal tumors of the ovary: Epidemiology, clinical features, and diagnosis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1399626360">
         <span class="h1">
          INITIAL PRESENTATION
         </span>
        </p>
        <p class="headingAnchor" id="H997006092">
         <span class="h2">
          General surgical considerations for patients with an ovarian neoplasm
         </span>
         <span class="headingEndMark">
          —
         </span>
         In all patients with an ovarian mass, surgery is performed for diagnosis and initial treatment if ultrasound findings suggest the mass has some reasonable chance of being malignant  (
         <a class="graphic graphic_table graphicRef79259" href="/z/d/graphic/79259.html" rel="external">
          table 2
         </a>
         ). Surgery to resect the mass is also performed if there are other risks associated with it (eg, torsion) or if the mass is causing symptoms. Patients with SCSTs generally meet one or more of these criteria.
        </p>
        <p>
         Preoperative patient preparation is routine, except in patients with virilization or signs of estrogen excess in whom assessing for tumor markers and performing endometrial sampling to detect a possible endometrial neoplasm may be indicated. (See
         <a class="medical medical_review" href="/z/d/html/16833.html" rel="external">
          "Sex cord-stromal tumors of the ovary: Epidemiology, clinical features, and diagnosis in adults", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
         Preoperative counseling and informed consent should include the planned procedure for benign, malignant, or indeterminate intraoperative findings and issues regarding fertility preservation. This discussion should be documented in the medical record.
        </p>
        <p>
         Oophorectomy is adequate therapy for a benign SCST; ovarian cystectomy may be performed if complete excision is possible and the patient desires preservation of the ovary. An exception is patients with a thecoma in the menopausal transition or postmenopause. Although thecomas are benign, we suggest a total hysterectomy with bilateral salpingo-oophorectomy for these patients because thecomas commonly cause estrogenic effects, so a synchronous endometrial neoplasm may be present (eg, endometrial cancer, endometrial stromal sarcoma) [
         <a href="#rid1">
          1,2
         </a>
         ]. However, unilateral oophorectomy is an option in young patients when preservation of fertility or avoidance of exogenous hormone replacement is desired [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Management of malignant SCSTs is more aggressive and varies with the histologic diagnosis. Since a definitive diagnosis is often not made pre- or intraoperatively, the surgeon will need to make an intraoperative decision about which surgical option to employ based on imperfect histologic information, gross operative findings (eg, disease beyond the ovary), and the patient's preferences. Since these are rare neoplasms, even expert gynecologic pathologists may not provide a definite diagnosis based on intraoperative frozen section examination. Epithelial neoplasms (particularly endometrioid carcinoma) can mimic SCST neoplasms, and, if the diagnosis is uncertain, the pathologist should communicate this to the surgeon (and patient).
        </p>
        <p>
         When an intraoperative frozen section is indeterminate, a young patient with a unilateral ovarian mass desirous of fertility preservation may opt for conservative surgery (oophorectomy), whereas a postmenopausal patient with a unilateral ovarian mass may prefer a hysterectomy with bilateral salpingo-oophorectomy. In patients who opt for conservative surgery, issues regarding incomplete staging and the potential need for further surgery if the definitive diagnosis is malignant neoplasm should be discussed.
        </p>
        <p class="headingAnchor" id="H2988498605">
         <span class="h2">
          Surgical management of patients with malignant SCSTs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Malignant ovarian SCSTs are surgically staged, which can be done by an open procedure or laparoscopically.
        </p>
        <p>
         The staging system for all primary ovarian cancers is the same  (
         <a class="graphic graphic_table graphicRef113545" href="/z/d/graphic/113545.html" rel="external">
          table 3
         </a>
         ) regardless of histology (SCST, epithelial cell, germ cell). The stage is the most important factor in determining prognosis and guiding postoperative treatment recommendations [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Complete surgical staging is generally similar to that for patients with ovarian carcinoma (see
         <a class="medical medical_review" href="/z/d/html/3193.html" rel="external">
          "Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Surgical staging"
         </a>
         ). One notable difference is that we suggest not performing pelvic and paraaortic lymphadenectomy in most patients with confirmed or suspected SCSTs because lymph node metastases are rare with these tumors [
         <a href="#rid5">
          5
         </a>
         ], and lymphadenectomy may result in lymphedema that impacts quality of life [
         <a href="#rid6">
          6,7
         </a>
         ]. Instead, the pelvic and paraaortic nodes should be palpated and lymphadenectomy limited to those with palpable nodal enlargement or a definitive histologic diagnosis of a non-SCST ovarian tumor. (See
         <a class="medical medical_review" href="/z/d/html/755.html" rel="external">
          "Clinical features and diagnosis of peripheral lymphedema"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7645.html" rel="external">
          "Cellulitis following pelvic lymph node dissection"
         </a>
         .)
        </p>
        <p>
         Total hysterectomy and bilateral salpingo-oophorectomy is a component of surgical staging and treatment of ovarian cancer, but fertility preservation is an acceptable option for young patients with ovarian tumors confined to the ovary. For example, granulosa cell and Sertoli-Leydig cell tumors are generally confined to one ovary. For patients with apparent stage I disease who wish to preserve fertility or avoid exogenous hormone replacement, a unilateral salpingo-oophorectomy and uterine preservation with other procedures for complete surgical staging are appropriate  (
         <a class="graphic graphic_table graphicRef75194" href="/z/d/graphic/75194.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid3">
          3,8,9
         </a>
         ]. Retrospective studies suggest an equivalent cure rate for early-stage disease whether treated by unilateral salpingo-oophorectomy or bilateral salpingo-oophorectomy [
         <a href="#rid3">
          3,9,10
         </a>
         ]. The contralateral ovary should be carefully inspected; biopsy is necessary only if an abnormality is found. If hysterectomy is not performed and endometrial sampling was not performed preoperatively, it should be performed intraoperatively to rule out an endometrial neoplasm in the setting of an estrogen-secreting SCST, particularly granulosa cell tumors.
        </p>
        <p>
         Surgical management is similar for other SCSTs. The National Comprehensive Cancer Network (NCCN) recommends consideration of total hysterectomy with bilateral salpingo-oophorectomy after childbearing is completed [
         <a href="#rid8">
          8
         </a>
         ]. When surgical staging is performed, it can often be completed laparoscopically. In a retrospective study of 81 patients undergoing a re-staging procedure for incompletely staged granulosa cell tumors, laparoscopy was similar to an open approach in terms of ability to complete the staging procedure and percentage of patients who were upstaged; no major intraoperative or postoperative complications occurred in either group [
         <a href="#rid11">
          11
         </a>
         ]. A concern among gynecologic oncologists has been ovarian rupture during minimally invasive surgery for an unexpected ovarian malignancy, potentially converting stage IA to IC [
         <a href="#rid12">
          12,13
         </a>
         ]. However, further study is required to understand whether the rate of ovarian rupture is higher with minimally invasive versus open surgery. (See
         <a class="medical medical_review" href="/z/d/html/3193.html" rel="external">
          "Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Surgical staging", section on 'Open laparotomy versus minimally invasive surgery'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1869479522">
         <span class="h2">
          Adjuvant therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The choice to proceed with adjuvant treatment should be guided by an individualized discussion of goals and preferences, acknowledging the lack of data to support its use. Due to the rarity of ovarian SCSTs, no prospective, randomized clinical trial data exist.
        </p>
        <p class="headingAnchor" id="H4165872145">
         <span class="h3">
          Granulosa cell tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgery alone is acceptable treatment for most patients with granulosa cell tumors since the majority are stage IA and confined to one ovary at the time of diagnosis  (
         <a class="graphic graphic_table graphicRef113545" href="/z/d/graphic/113545.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]. Long-term, disease-free survival rates are approximately 90 percent. For those with stage IC and higher disease, we suggest adjuvant chemotherapy given evidence suggesting this is a risk factor for recurrence [
         <a href="#rid14">
          14
         </a>
         ], although the approach to such patients is controversial, and observation is also an acceptable strategy in patients with IC disease, per NCCN guidelines [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         The rarity of granulosa cell tumors makes it difficult to conduct well-designed randomized studies to define the value of any strategy. As a result, the benefit of postoperative treatment is unclear, and practice is variable. While some centers recommend adjuvant therapy for all patients with stage IC to IV disease, others reserve this recommendation for patients over the age of 40 at diagnosis who, in one early series, had a higher risk of disease recurrences compared with younger patients [
         <a href="#rid15">
          15
         </a>
         ], though other reports have failed to confirm the adverse impact of older age on outcomes [
         <a href="#rid16">
          16-22
         </a>
         ]. Other centers recommend adjuvant therapy only for patients with residual disease after surgery, and still others do not recommend adjuvant therapy for any stage of disease, treating only at the time of a recurrence.
        </p>
        <p>
         Although adjuvant chemotherapy has been associated with longer progression-free survival (PFS) among those with advanced granulosa cell tumors, there is no evidence supporting an overall survival benefit. The following represents the range of findings regarding the benefit of adjuvant therapy from observational studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For children with advanced-stage juvenile granulosa cell tumors, adjuvant chemotherapy appears to contribute to long-lasting complete remission and is usually recommended for those with stage IC disease and a high mitotic index (≥20 per 10 high power fields), as well as those with more advanced-stage disease [
         <a href="#rid23">
          23-29
         </a>
         ]. However, it is difficult to extrapolate these results to adult-type tumors, which have a different biology (ie, lower proliferative rate and greater risk of late recurrences) than the juvenile type.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Excellent outcomes were demonstrated in an observational study of 160 patients with stage I granulosa cell tumors, most of whom (98 percent) did not receive adjuvant chemotherapy [
         <a href="#rid30">
          30
         </a>
         ]. At a median follow-up of 7 years, 32 percent had relapsed, but median overall survival was similar in patients with (24 years) and without relapse (22 years). Surgery was the main therapeutic modality at relapse, although most patients (86 percent) also received some form of nonsurgical therapy. Similarly, in the MITO-9 study, among 35 patients with recurrent granulosa cell tumors, receipt of adjuvant chemotherapy at initial presentation was associated with improvements in recurrence-free survival (73 versus 48 months) but not overall survival.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some retrospective series of adults with granulosa cell tumor suggest that patients with advanced (stage III/IV) disease who receive postoperative chemotherapy have a longer progression-free interval than those who do not [
         <a href="#rid31">
          31
         </a>
         ]. However, others have failed to show that the use of chemotherapy is associated with better survival [
         <a href="#rid32">
          32-36
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Despite the lack of survival benefit, we and others suggest postoperative chemotherapy for patients with resected stage IC to IV disease because of the high risk of disease progression and the potential for long-term survival in patients with advanced disease who receive modern platinum-based chemotherapy [
         <a href="#rid23">
          23,37-42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3155856669">
         <span class="h3">
          Sertoli-Leydig cell tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The available data evaluating the benefit of chemotherapy in Sertoli-Leydig cell tumors are scant, with most of the literature consisting of isolated case reports. Together, these data suggest the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For
         <strong>
          most
         </strong>
         patients with well-differentiated, stage I tumors, we suggest surgery alone (without adjuvant chemotherapy), given that such tumors have a typically good prognosis. However, for tumors that contain either heterologous elements or retiform pattern, the relapse rate is as high as 20 percent; for patients with these histologies, we suggest platinum-based chemotherapy [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with poorly differentiated Sertoli-Leydig cell tumors, the relapse rate is up to 60 percent; therefore, for patients with intermediate- to high-grade, stage I tumors, or higher stage tumors of any grade, we suggest adjuvant platinum-based chemotherapy [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Examples of outcomes with adjuvant chemotherapy in Sertoli-Leydig cell tumors are as follows for stage I disease:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One series included three patients with stage IC Sertoli-Leydig cell tumor, two of which were poorly differentiated and one of which had intermediate differentiation [
         <a href="#rid23">
          23
         </a>
         ]. Despite the early use of platinum-based chemotherapy, only the patient with a tumor of intermediate differentiation was disease-free at 47 months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a multi-institutional Italian study including 21 patients with nonmetastatic Sertoli-Leydig cell tumors, five patients received adjuvant chemotherapy [
         <a href="#rid43">
          43
         </a>
         ]. Of the three patients with stage IA tumors of intermediate differentiation who relapsed (none of whom received initial chemotherapy), two died of disease. Of four patients with stage IA poorly differentiated tumors, only one received adjuvant chemotherapy, and all four were alive and free of disease at the time of the report.
        </p>
        <p>
        </p>
        <p>
         For those with higher stage tumors, although objective response rates are high [
         <a href="#rid39">
          39
         </a>
         ], responses are typically not durable. For example, in an observational study of nine patients with metastatic ovarian SCSTs of all types and poorly differentiated Sertoli-Leydig cell tumors confined to the ovary, overall response rate was 83 percent, but PFS was just 14 months [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2041393035">
         <span class="h3">
          Other types of SCST
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with stage II to IV disease of any cell type have an increased risk of recurrence compared with those with stage I disease. Therefore, adjuvant platinum-based chemotherapy is generally offered [
         <a href="#rid39">
          39,44,45
         </a>
         ], although there are other data to suggest that it may not provide a survival advantage [
         <a href="#rid46">
          46
         </a>
         ]. In the absence of a randomized trial comparing chemotherapy with observation, we continue to suggest adjuvant chemotherapy to these patients.
        </p>
        <p class="headingAnchor" id="H699671453">
         <span class="h3">
          Choice of regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most commonly used regimens for patients with SCSTs are
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         , plus
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         (BEP)  (
         <a class="graphic graphic_table graphicRef122985" href="/z/d/graphic/122985.html" rel="external">
          table 5
         </a>
         ), as is used for testicular and ovarian germ cell tumors, or
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         plus
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         (PC) [
         <a href="#rid37">
          37
         </a>
         ]. For younger, fit patients, we typically opt for BEP, while we prefer PC for patients &gt;40 years old, due to toxicity concerns. (See
         <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">
          "Initial risk-stratified treatment for advanced testicular germ cell tumors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3197.html" rel="external">
          "Treatment of malignant germ cell tumors of the ovary"
         </a>
         .)
        </p>
        <p>
         GOG 264 was a phase II trial to determine the PFS of PC versus BEP for treatment of newly diagnosed stage IIA to IV or recurrent chemotherapy-naïve ovarian sex cord-stromal tumors. Sixty-three patients were accrued at the interim futility analysis. The study was closed early for futility because compared with BEP, PC failed to improve PFS [
         <a href="#rid47">
          47
         </a>
         ]. However, as presented at the 2020 International Gynecologic Cancer Society meeting, PC showed a more favorable side effect profile (hazard ratio 1.12, 95% CI 0.58-2.16). Median PFS was 27.7 months for PC and 19.7 months for BEP (95% CI 10.4-52.7).
        </p>
        <p class="headingAnchor" id="H2036688057">
         <span class="h4">
          Role for radiation therapy?
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with chemotherapy, there are no prospective randomized trials that define the value of postoperative radiation therapy (RT). RT has been used for both granulosa cell tumors and Sertoli-Leydig cell tumors. However, most reports have evaluated only granulosa cell tumors and are not contemporary. As such, RT is rarely used. For those with granulosa cell tumors who are appropriate candidates for adjuvant treatment, we typically suggest chemotherapy alone, although some experts may offer radiation as an acceptable alternative for those with disease limited to the pelvis.
        </p>
        <p>
         In the adjuvant setting, an older retrospective series is often quoted as supporting benefit from RT [
         <a href="#rid18">
          18
         </a>
         ]. However, insufficient data were provided to determine whether the differences in outcome between irradiated and nonirradiated patients were attributable to therapy. Several later observational series fail to show any benefit from adjuvant radiation [
         <a href="#rid16">
          16,17,19,40,48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2935466363">
         <span class="h2">
          Posttreatment surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no high-quality evidence to support one posttreatment surveillance strategy over another for ovarian SCSTs. We follow guidelines from the Society of Gynecologic Oncologists and the NCCN [
         <a href="#rid8">
          8,49
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Review of symptoms and physical examination
         </strong>
         – For the first two years, every two to four months; then every six months thereafter.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serum tumor markers
         </strong>
         – For patients in whom one or more tumor markers (eg, testosterone, inhibin, alpha-fetoprotein, anti-müllerian hormone) were elevated at diagnosis, the same markers should be repeated every two to four months for the first two years and then every six months thereafter. Monitoring multiple markers rather than a single marker appears to be superior for detection of macroscopic disease [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Symptoms are also an indication for checking serum tumor marker levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Routine use of imaging studies is not recommended. Computed tomography or other imaging is usually reserved for evaluation of patients with symptoms or elevation in a serum tumor marker level.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H257262250">
         <span class="h1">
          RECURRENT DISEASE
         </span>
        </p>
        <p class="headingAnchor" id="H625745560">
         <span class="h2">
          Surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are few data on the optimal management of patients who experience recurrent disease. However, if the recurrence appears resectable, low-quality data primarily obtained in studies of patients with recurrent granulosa cell tumors suggest that surgical treatment may afford a survival advantage [
         <a href="#rid22">
          22,51
         </a>
         ]. In a series of 16 patients with recurrent adult granulosa cell tumor who underwent salvage surgery, maximal debulking was achieved in 13 patients [
         <a href="#rid52">
          52
         </a>
         ]. Multifocal recurrent disease and residual tumor after surgery were associated with diminished progression-free and overall survival (31 versus 207 months and 22 versus 220 months, respectively). Use of adjuvant systemic treatment is discussed below. (See
         <a class="local">
          'Systemic therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1078177329">
         <span class="h2">
          Systemic therapy
         </span>
        </p>
        <p class="headingAnchor" id="H940876594">
         <span class="h3">
          Choice of regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients, adjuvant systemic treatment is suggested. For patients who are not candidates for surgery (either due to performance status or extent of disease) or for those who experience multiple recurrences, medical therapy alone is generally suggested.
        </p>
        <p>
         Based on their use in the adjuvant setting [
         <a href="#rid39">
          39,41,44,45
         </a>
         ],
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         , plus
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (BEP) and
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         plus
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         (PC) are the most commonly utilized platinum-based regimens for these patients. Although the data are limited, angiogenesis inhibitors, hormonal therapy (including
         <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">
          leuprolide
         </a>
         acetate,
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         , or the aromatase inhibitors), and radiation therapy (RT) have also demonstrated activity, particularly for the treatment of adult-type granulosa cell tumors [
         <a href="#rid37">
          37,40,53-58
         </a>
         ]. (See
         <a class="local">
          'Granulosa cell tumors'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3886584294">
         <span class="h3">
          Granulosa cell tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         As discussed above, adjuvant chemotherapy is typically offered to those who have undergone surgery for relapsed disease. It is also used for those who are not appropriate candidates for surgery or have unresectable disease. This and other options are discussed below.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chemotherapy
         </strong>
         – Chemotherapeutic options may include retreatment with a platinum-based regimen (BEP or PC). Typically, if BEP was used previously, PC is chosen at relapse and vice versa (although BEP is often avoided in patients older than 40 years due to toxicity concerns). The value of taxanes, particularly in combination with platinum agents, has been reported [
         <a href="#rid45">
          45,59-61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A response rate of 29 percent has been reported in patients with recurrent SCSTs treated with single-agent
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         [
         <a href="#rid62">
          62
         </a>
         ]. Other chemotherapeutic regimens with reported therapeutic efficacy include
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         alone [
         <a href="#rid63">
          63
         </a>
         ];
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         plus
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         [
         <a href="#rid64">
          64
         </a>
         ];
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">
          vinblastine
         </a>
         , plus
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         (PVB or VBP) [
         <a href="#rid65">
          65
         </a>
         ]; and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , doxorubicin, plus cisplatin (CAP) [
         <a href="#rid66">
          66-68
         </a>
         ]. None of these regimens have produced consistently better results than those seen with BEP, but they may be considered for second-line therapy. Other empirical options include drugs used for platinum-resistant epithelial ovarian cancer, including
         <a class="drug drug_general" data-topicid="10135" href="/z/d/drug information/10135.html" rel="external">
          pegylated liposomal doxorubicin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         /cisplatin, or
         <a class="drug drug_general" data-topicid="10007" href="/z/d/drug information/10007.html" rel="external">
          topotecan
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hormonal therapy
         </strong>
         – Experimental data and small clinical series suggest that hormonal agents such as luteinizing hormone-releasing hormone agonists (eg,
         <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">
          leuprolide
         </a>
         ) might be effective in granulosa cell tumors through the suppression of gonadotropin secretion [
         <a href="#rid54">
          54,55,69-71
         </a>
         ]. However, others have failed to document efficacy [
         <a href="#rid40">
          40,72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Low-quality data indicate that treatment of recurrent disease with aromatase inhibitors,
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         alone,
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         alone, or a combination of tamoxifen and progesterone occasionally can result in long-term clinical responses. In a systematic review including nine patients with granulosa cell tumors receiving an aromatase inhibitor, all experienced a complete or partial response [
         <a href="#rid73">
          73
         </a>
         ]. Similarly, in one case report, a complete clinical response in a patient with recurrent granulosa cell tumor was achieved using alternating biweekly cycles of megestrol 40 mg twice daily for two weeks, alternating with two week courses of tamoxifen 10 mg twice daily [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other systemic agents
         </strong>
         – Antiangiogenic therapy appears promising. In an early report of eight patients with granulosa cell tumors,
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         , a monoclonal antibody directed against the vascular endothelial growth factor, induced a complete clinical response in one patient, partial responses in two, and stable disease in two others [
         <a href="#rid74">
          74
         </a>
         ]. A GOG phase II trial of bevacizumab in patients with metastatic SCSTs was reported [
         <a href="#rid58">
          58
         </a>
         ]. Of the 36 patients enrolled, 88.9 percent had granulosa cell tumors. The response rate was 16.7 percent, and 77.8 percent had stable disease. The median progression-free survival was 9.3 months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Because available effective therapies for patients with metastatic disease are limited, genomic profiling may be pursued to identify common mutations that may be targetable by novel agents, either off-label or in clinical trials [
         <a href="#rid75">
          75
         </a>
         ]. In a study reporting the largest molecularly profiling dataset described to date for adult granulosa cell tumor, genomic profiling of 423 tumors revealed no tumors with microsatellite instability, and none had high genomic loss of heterozygosity [
         <a href="#rid76">
          76
         </a>
         ]. The most common aberrations included
         <em>
          TERT
         </em>
         promoter mutations, 9.2 percent;
         <em>
          KMT2D
         </em>
         mutations, 16.8 percent;
         <em>
          TP53
         </em>
         mutations, 8.3 percent;
         <em>
          CDKN2A
         </em>
         and/or
         <em>
          CDKN2B
         </em>
         deletions, 10.2 percent; and activating
         <em>
          PIK3CA
         </em>
         mutations, 5.4 percent. This information will hopefully serve as hypothesis-generating data for future clinical trials.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Radiation therapy
         </strong>
         – RT can induce clinical responses and occasional long-term remission in patients with persistent or recurrent granulosa cell tumors [
         <a href="#rid37">
          37,40,53
         </a>
         ]. In one review of 34 patients treated at a single center over a 40-year period with radiation alone, 3 of the 14 who were treated for measurable disease were alive without progression 10 to 21 years following treatment [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H502778256">
         <span class="h3">
          Sertoli-Leydig cell tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         For those with relapsed Sertoli-Leydig cell tumors who have undergone repeat surgical resection, chemotherapy is typically offered adjuvantly, though a possible exception is for patients with well-differentiated Sertoli-Leydig cell tumors who relapse and have no change in histology; for such patients, surgery alone may be sufficient. Chemotherapy is also used as primary treatment for those with unresectable disease or for those who are poor surgical candidates [
         <a href="#rid39">
          39,44,45,67,77-79
         </a>
         ]. This and other options are discussed below.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chemotherapy
         </strong>
         – As with granulosa cell tumors, the optimal regimen for treatment of advanced Sertoli-Leydig cell tumors is unknown. However, we suggest platinum-based chemotherapy. If BEP has not been used, and the patient is ≤40 years old, it is our preferred option. For those over 40 years of age or those who have previously been treated with BEP, we opt for PC. Other platinum-based regimens are alternatives. These include CAP;
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8663" href="/z/d/drug information/8663.html" rel="external">
          epirubicin
         </a>
         , plus
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         ; PVB or VBP; and taxane/platinum combination therapy [
         <a href="#rid39">
          39,44,45,67,77-79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other systemic agents
         </strong>
         – Although chemotherapy is typically preferred, other agents may be appropriate as later line therapy: for example, angiogenesis inhibitors as for granulosa cell tumors. (See
         <a class="local">
          'Granulosa cell tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, endocrine therapy is typically not used for Sertoli-Leydig cell tumors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Radiation therapy
         </strong>
         – Extrapolating from data in recurrent granulosa cell tumors, RT may be offered for those with multiply relapsed Sertoli-Leydig cell tumors, though data are limited. (See
         <a class="local">
          'Granulosa cell tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2824228530">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Generally, malignant SCSTs are diagnosed at an early stage and have low-grade histology, and thus have a good prognosis. However, some tumors are aggressive and have a lethal outcome. Outcomes related to specific histologies are discussed below.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Granulosa cell tumors
         </strong>
         – The prognosis of ovarian granulosa cell tumor depends on the stage of disease at diagnosis and the presence of residual disease after surgery  (
         <a class="graphic graphic_table graphicRef67595" href="/z/d/graphic/67595.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid34">
          34,37,48,80-82
         </a>
         ]. Five-year survival rates for completely resected stage I disease are approximately 90 percent [
         <a href="#rid34">
          34,38,48
         </a>
         ], but outcomes tend to be less favorable in the presence of a large tumor size (10 to 15 cm) or (in many but not all series [
         <a href="#rid22">
          22
         </a>
         ]) tumor rupture [
         <a href="#rid14">
          14,16,19,20,48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A number of histologic features have also been examined for their prognostic significance. In adults, cellular atypia, high mitotic index (4 to 10 mitoses per 10 high power fields), and the absence of Call-Exner bodies are the only significant histologic predictors of early recurrence [
         <a href="#rid4">
          4,22,48
         </a>
         ]. Abnormal karyotype, p53 overexpression, and ploidy do not appear to be of prognostic value [
         <a href="#rid83">
          83,84
         </a>
         ]. There are conflicting reports regarding the prognostic influence of other factors, such as positive cytology, tumor size, ovarian surface involvement, and ploidy status. Further studies are needed in this area.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Ovarian granulosa cell tumors have metastatic potential and a tendency for late relapse. In one report of 37 patients with stage I disease, survival rates at 5, 10, and 20 years were 94, 82, and 62 percent, respectively [
         <a href="#rid38">
          38
         </a>
         ]. The median time to relapse is approximately four to six years after initial diagnosis; however, late recurrences have been reported after as many as 40 years [
         <a href="#rid4">
          4,16,38,48,85,86
         </a>
         ]. Thus, prolonged surveillance with serial physical examinations and serum tumor markers (particularly inhibin) should be performed [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sertoli-Leydig cell tumors
         </strong>
         – The overall five-year survival is 70 to 90 percent and is related to stage and degree of histologic differentiation [
         <a href="#rid43">
          43,87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3164570769">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119533.html" rel="external">
          "Society guideline links: Ovarian, fallopian tube, and peritoneal cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4197552209">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/83539.html" rel="external">
          "Patient education: Sertoli-Leydig cell tumor (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3739423732">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Staging of malignant sex cord-stromal tumors (SCSTs) is generally the same as for other primary ovarian malignant neoplasms  (
         <a class="graphic graphic_table graphicRef113545" href="/z/d/graphic/113545.html" rel="external">
          table 3
         </a>
         ) and typically includes total hysterectomy and bilateral salpingo-oophorectomy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         However, conservation of a contralateral ovary and/or the uterus if it has no evidence of disease is possible in patients who wish to preserve fertility, but the feasibility varies by tumor histology.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For most patients with malignant sex cord-stromal neoplasms, we suggest
         <strong>
          not
         </strong>
         performing pelvic and paraaortic lymphadenectomy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Lymphadenectomy is performed, however, for patients with palpable enlargement of these nodes and may be performed in patients in whom there is a suspicion of diagnosis of another histologic type of ovarian malignant neoplasm. (See
         <a class="medical medical_review" href="/z/d/html/16833.html" rel="external">
          "Sex cord-stromal tumors of the ovary: Epidemiology, clinical features, and diagnosis in adults", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with stage IA disease who have completed surgical treatment, our postoperative approach is as follows, though we recognize that alternative strategies are reasonable in the setting of limited data:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For those with granulosa cell tumors, we suggest posttreatment surveillance rather than adjuvant chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For those with Sertoli-Leydig cell tumors that are intermediate to high grade, or have heterologous or retiform pattern, we suggest adjuvant chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For those with well-differentiated tumors, observation alone is sufficient.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients whose neoplasm involves the ovarian surface (stage IC) or is more advanced (stage II or greater), we suggest adjuvant chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), although this is particularly controversial for those with stage IC disease, and observation is also an acceptable strategy in such patients. Note that stage IB disease is essentially nonexistent.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Regarding choice of regimen, for patients who are ≤40 years old, we suggest
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         , plus
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (BEP) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), while for those who are &gt;40 years old, we suggest
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         plus
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         (PC) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), given better tolerability than with BEP in this older subset. (See
         <a class="local">
          'Choice of regimen'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For most patients with recurrent disease that is resectable, we suggest surgical treatment (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For patients who have undergone resection, we suggest postoperative platinum-based chemotherapy rather than other regimens, postoperative radiation, or observation only (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Recurrent disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For most patients with recurrent disease who are not surgical candidates, we suggest platinum-based chemotherapy rather than other radiation therapy or other forms of medical therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), although reasonable alternatives include endocrine therapy (for granulosa cell tumors) or angiogenesis inhibitors. Because available effective therapies for patients with metastatic disease are limited, genomic profiling may be pursued to identify common mutations that may be targetable by novel agents in clinical trials. (See
         <a class="local">
          'Granulosa cell tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Press MF, Scully RE. Endometrial "sarcomas" complicating ovarian thecoma, polycystic ovarian disease and estrogen therapy. Gynecol Oncol 1985; 21:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Björkholm E, Silfverswärd C. Theca-cell tumors. Clinical features and prognosis. Acta Radiol Oncol 1980; 19:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gershenson DM. Management of early ovarian cancer: germ cell and sex cord-stromal tumors. Gynecol Oncol 1994; 55:S62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller BE, Barron BA, Wan JY, et al. Prognostic factors in adult granulosa cell tumor of the ovary. Cancer 1997; 79:1951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thrall MM, Paley P, Pizer E, et al. Patterns of spread and recurrence of sex cord-stromal tumors of the ovary. Gynecol Oncol 2011; 122:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown J, Sood AK, Deavers MT, et al. Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted? Gynecol Oncol 2009; 113:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu-Rustum NR, Restivo A, Ivy J, et al. Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary. Gynecol Oncol 2006; 103:31.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 2.2023. Available at: https://www.nccn.org/professionals/physician_gls/ https://www.nccn.org/professionals/physician_gls/ (Accessed on November 29, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang M, Cheung MK, Shin JY, et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women. Gynecol Oncol 2007; 104:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergamini A, Cormio G, Ferrandina G, et al. Conservative surgery in stage I adult type granulosa cells tumors of the ovary: Results from the MITO-9 study. Gynecol Oncol 2019; 154:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peiretti M, Candotti G, Fais ML, et al. Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary. Gynecol Oncol 2020; 157:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsushita H, Watanabe K, Yokoi T, Wakatsuki A. Unexpected ovarian malignancy following laparoscopic excision of adnexal masses. Hum Reprod 2014; 29:1912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muzii L, Angioli R, Zullo M, Panici PB. The unexpected ovarian malignancy found during operative laparoscopy: incidence, management, and implications for prognosis. J Minim Invasive Gynecol 2005; 12:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Auranen A, Sundström J, Ijäs J, Grénman S. Prognostic factors of ovarian granulosa cell tumor: a study of 35 patients and review of the literature. Int J Gynecol Cancer 2007; 17:1011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PE, Smith JP. Treatment of ovarian stromal tumors. Am J Obstet Gynecol 1976; 125:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans AT 3rd, Gaffey TA, Malkasian GD Jr, Annegers JF. Clinicopathologic review of 118 granulosa and 82 theca cell tumors. Obstet Gynecol 1980; 55:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohel G, Kaneti H, Schenker JG. Granulosa cell tumors in Israel: a study of 172 cases. Gynecol Oncol 1983; 15:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pankratz E, Boyes DA, White GW, et al. Granulosa cell tumors. A clinical review of 61 cases. Obstet Gynecol 1978; 52:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Björkholm E, Silfverswärd C. Prognostic factors in granulosa-cell tumors. Gynecol Oncol 1981; 11:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stenwig JT, Hazekamp JT, Beecham JB. Granulosa cell tumors of the ovary. A clinicopathological study of 118 cases with long-term follow-up. Gynecol Oncol 1979; 7:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox H, Agrawal K, Langley FA. A clinicopathologic study of 92 cases of granulosa cell tumor of the ovary with special reference to the factors influencing prognosis. Cancer 1975; 35:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sehouli J, Drescher FS, Mustea A, et al. Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients. Anticancer Res 2004; 24:1223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneider DT, Calaminus G, Wessalowski R, et al. Ovarian sex cord-stromal tumors in children and adolescents. J Clin Oncol 2003; 21:2357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young RH, Scully RE. Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J Surg Pathol 1985; 9:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young RH, Dickersin GR, Scully RE. Juvenile granulosa cell tumor of the ovary. A clinicopathological analysis of 125 cases. Am J Surg Pathol 1984; 8:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calaminus G, Wessalowski R, Harms D, Göbel U. Juvenile granulosa cell tumors of the ovary in children and adolescents: results from 33 patients registered in a prospective cooperative study. Gynecol Oncol 1997; 65:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneider DT, Calaminus G, Wessalowski R, et al. Therapy of advanced ovarian juvenile granulosa cell tumors. Klin Padiatr 2002; 214:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneider DT, Jänig U, Calaminus G, et al. Ovarian sex cord-stromal tumors--a clinicopathological study of 72 cases from the Kiel Pediatric Tumor Registry. Virchows Arch 2003; 443:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plantaz D, Flamant F, Vassal G, et al. [Granulosa cell tumors of the ovary in children and adolescents. Multicenter retrospective study in 40 patients aged 7 months to 22 years]. Arch Fr Pediatr 1992; 49:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson MK, Fong P, Mesnage S, et al. Stage I granulosa cell tumours: A management conundrum? Results of long-term follow up. Gynecol Oncol 2015; 138:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uygun K, Aydiner A, Saip P, et al. Clinical parameters and treatment results in recurrent granulosa cell tumor of the ovary. Gynecol Oncol 2003; 88:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zanagnolo V, Pasinetti B, Sartori E. Clinical review of 63 cases of sex cord stromal tumors. Eur J Gynaecol Oncol 2004; 25:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Badawi IA, Brasher PM, Ghatage P, et al. Postoperative chemotherapy in advanced ovarian granulosa cell tumors. Int J Gynecol Cancer 2002; 12:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan JK, Zhang M, Kaleb V, et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--a multivariate analysis. Gynecol Oncol 2005; 96:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seagle BL, Ann P, Butler S, Shahabi S. Ovarian granulosa cell tumor: A National Cancer Database study. Gynecol Oncol 2017; 146:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oseledchyk A, Gennarelli RL, Leitao MM Jr, et al. Adjuvant chemotherapy in patients with operable granulosa cell tumors of the ovary: a surveillance, epidemiology, and end results cohort study. Cancer Med 2018; 7:2280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol 2003; 21:1180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lauszus FF, Petersen AC, Greisen J, Jakobsen A. Granulosa cell tumor of the ovary: a population-based study of 37 women with stage I disease. Gynecol Oncol 2001; 81:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Homesley HD, Bundy BN, Hurteau JA, Roth LM. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study. Gynecol Oncol 1999; 72:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savage P, Constenla D, Fisher C, et al. Granulosa cell tumours of the ovary: demographics, survival and the management of advanced disease. Clin Oncol (R Coll Radiol) 1998; 10:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colombo N, Sessa C, Landoni F, et al. Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary. Obstet Gynecol 1986; 67:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zambetti M, Escobedo A, Pilotti S, De Palo G. cis-platinum/vinblastine/bleomycin combination chemotherapy in advanced or recurrent granulosa cell tumors of the ovary. Gynecol Oncol 1990; 36:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sigismondi C, Gadducci A, Lorusso D, et al. Ovarian Sertoli-Leydig cell tumors. a retrospective MITO study. Gynecol Oncol 2012; 125:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gershenson DM, Morris M, Burke TW, et al. Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin. Obstet Gynecol 1996; 87:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown J, Shvartsman HS, Deavers MT, et al. The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J Clin Oncol 2004; 22:3517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hölscher G, Anthuber C, Bastert G, et al. Improvement of survival in sex cord stromal tumors - an observational study with more than 25 years follow-up. Acta Obstet Gynecol Scand 2009; 88:440.
          </a>
         </li>
         <li class="breakAll">
          NRG Oncology winter 2021 virtual meeting program book. https://www.nrgoncology.org/LinkClick.aspx?fileticket=VvIsMs5hK0Y%3D&amp;portalid=0 (Accessed on September 28, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malmström H, Högberg T, Risberg B, Simonsen E. Granulosa cell tumors of the ovary: prognostic factors and outcome. Gynecol Oncol 1994; 52:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011; 204:466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Färkkilä A, Koskela S, Bryk S, et al. The clinical utility of serum anti-Müllerian hormone in the follow-up of ovarian adult-type granulosa cell tumors--A comparative study with inhibin B. Int J Cancer 2015; 137:1661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mangili G, Sigismondi C, Frigerio L, et al. Recurrent granulosa cell tumors (GCTs) of the ovary: a MITO-9 retrospective study. Gynecol Oncol 2013; 130:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karalok A, Ureyen I, Tasci T, et al. Maximum surgical effort is warranted for recurrent adult granulosa cell tumors of ovary. Tumori 2016; 102:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolf JK, Mullen J, Eifel PJ, et al. Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary. Gynecol Oncol 1999; 73:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martikainen H, Penttinen J, Huhtaniemi I, Kauppila A. Gonadotropin-releasing hormone agonist analog therapy effective in ovarian granulosa cell malignancy. Gynecol Oncol 1989; 35:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishman A, Kudelka AP, Tresukosol D, et al. Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. J Reprod Med 1996; 41:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korach J, Perri T, Beiner M, et al. Promising effect of aromatase inhibitors on recurrent granulosa cell tumors. Int J Gynecol Cancer 2009; 19:830.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alhilli MM, Long HJ, Podratz KC, Bakkum-Gamez JN. Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature. J Obstet Gynaecol Res 2012; 38:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown J, Brady WE, Schink J, et al. Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group. Cancer 2014; 120:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tresukosol D, Kudelka AP, Edwards CL, et al. Recurrent ovarian granulosa cell tumor: a case report of a dramatic response to Taxol. Int J Gynecol Cancer 1995; 5:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown J, Shvartsman HS, Deavers MT, et al. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol 2005; 97:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powell JL, Connor GP, Henderson GS. Management of recurrent juvenile granulosa cell tumor of the ovary. Gynecol Oncol 2001; 81:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burton ER, Brady M, Homesley HD, et al. A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study. Gynecol Oncol 2016; 140:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Disaia P, Saltz A, Kagan AR, Rich W. A temporary response of recurrent granulosa cell tumor to adriamycin. Obstet Gynecol 1978; 52:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powell JL, Otis CN. Management of advanced juvenile granulosa cell tumor of the ovary. Gynecol Oncol 1997; 64:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Segal R, DePetrillo AD, Thomas G. Clinical review of adult granulosa cell tumors of the ovary. Gynecol Oncol 1995; 56:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muntz HG, Goff BA, Fuller AF Jr. Recurrent ovarian granulosa cell tumor: role of combination chemotherapy with report of a long-term response to a cyclophosphamide, doxorubicin and cisplatin regimen. Eur J Gynaecol Oncol 1990; 11:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gershenson DM, Copeland LJ, Kavanagh JJ, et al. Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide. Obstet Gynecol 1987; 70:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pectasides D, Alevizakos N, Athanassiou AE. Cisplatin-containing regimen in advanced or recurrent granulosa cell tumours of the ovary. Ann Oncol 1992; 3:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emons G, Schally AV. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod 1994; 9:1364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Briasoulis E, Karavasilis V, Pavlidis N. Megestrol activity in recurrent adult type granulosa cell tumour of the ovary. Ann Oncol 1997; 8:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hardy RD, Bell JG, Nicely CJ, Reid GC. Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature. Gynecol Oncol 2005; 96:865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maxwell GL, Soisson AP, Miles P. Failure of gonadotropin releasing hormone therapy in patients with metastatic ovarian sex cord stromal tumors. Oncology 1994; 51:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Meurs HS, van Lonkhuijzen LR, Limpens J, et al. Hormone therapy in ovarian granulosa cell tumors: a systematic review. Gynecol Oncol 2014; 134:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tao X, Sood AK, Deavers MT, et al. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol 2009; 114:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Deiry WS, Goldberg RM, Lenz HJ, et al. The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA Cancer J Clin 2019; 69:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hillman RT, Lin DI, Lawson B, Gershenson DM. Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors. Gynecol Oncol 2021; 162:728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomlinson MW, Treadwell MC, Deppe G. Platinum based chemotherapy to treat recurrent Sertoli-Leydig cell ovarian carcinoma during pregnancy. Eur J Gynaecol Oncol 1997; 18:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujimoto A, Saitou M, Ishihara O, et al. [A case of ovarian malignant Sertoli-Leidig cell tumor treated with CBDCA, etoposide and epirubicin chemotherapy]. Gan To Kagaku Ryoho 1995; 22:1843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Meer J, de Vries EG, Vriesendorp R, et al. Hemolytic uremic syndrome in a patient on cis-platinum, vinblastine and bleomycin. J Cancer Res Clin Oncol 1985; 110:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cronjé HS, Niemand I, Bam RH, Woodruff JD. Review of the granulosa-theca cell tumors from the emil Novak ovarian tumor registry. Am J Obstet Gynecol 1999; 180:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uygun K, Aydiner A, Saip P, et al. Granulosa cell tumor of the ovary: retrospective analysis of 45 cases. Am J Clin Oncol 2003; 26:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee YK, Park NH, Kim JW, et al. Characteristics of recurrence in adult-type granulosa cell tumor. Int J Gynecol Cancer 2008; 18:642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ala-Fossi SL, Mäenpää J, Aine R, et al. Prognostic significance of p53 expression in ovarian granulosa cell tumors. Gynecol Oncol 1997; 66:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roush GR, el-Naggar AK, Abdul-Karim FW. Granulosa cell tumor of ovary: a clinicopathologic and flow cytometric DNA analysis. Gynecol Oncol 1995; 56:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crew KD, Cohen MH, Smith DH, et al. Long natural history of recurrent granulosa cell tumor of the ovary 23 years after initial diagnosis: a case report and review of the literature. Gynecol Oncol 2005; 96:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishiko O, Yoshida H, Sumi T, et al. Vascular endothelial growth factor levels in pleural and peritoneal fluid in Meigs' syndrome. Eur J Obstet Gynecol Reprod Biol 2001; 98:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gui T, Cao D, Shen K, et al. A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors. Gynecol Oncol 2012; 127:384.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 126385 Version 8.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2985476" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Endometrial "sarcomas" complicating ovarian thecoma, polycystic ovarian disease and estrogen therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6257044" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Theca-cell tumors. Clinical features and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7530680" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Management of early ovarian cancer: germ cell and sex cord-stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9149022" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Prognostic factors in adult granulosa cell tumor of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21481441" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Patterns of spread and recurrence of sex cord-stromal tumors of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19162310" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16537089" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16537089" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17030354" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31189500" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Conservative surgery in stage I adult type granulosa cells tumors of the ovary: Results from the MITO-9 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31954531" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24964925" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Unexpected ovarian malignancy following laparoscopic excision of adnexal masses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15904606" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The unexpected ovarian malignancy found during operative laparoscopy: incidence, management, and implications for prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17374124" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Prognostic factors of ovarian granulosa cell tumor: a study of 35 patients and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1275030" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Treatment of ovarian stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6243409" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clinicopathologic review of 118 granulosa and 82 theca cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6832637" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Granulosa cell tumors in Israel: a study of 172 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/733139" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Granulosa cell tumors. A clinical review of 61 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7250754" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Prognostic factors in granulosa-cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/437566" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Granulosa cell tumors of the ovary. A clinicopathological study of 118 cases with long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1109770" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A clinicopathologic study of 92 cases of granulosa cell tumor of the ovary with special reference to the factors influencing prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15154651" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12805338" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Ovarian sex cord-stromal tumors in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3911780" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6465418" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Juvenile granulosa cell tumor of the ovary. A clinicopathological analysis of 125 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9190974" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Juvenile granulosa cell tumors of the ovary in children and adolescents: results from 33 patients registered in a prospective cooperative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12165898" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Therapy of advanced ovarian juvenile granulosa cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12910419" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Ovarian sex cord-stromal tumors--a clinicopathological study of 72 cases from the Kiel Pediatric Tumor Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1300967" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : [Granulosa cell tumors of the ovary in children and adolescents. Multicenter retrospective study in 40 patients aged 7 months to 22 years].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26003143" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Stage I granulosa cell tumours: A management conundrum? Results of long-term follow up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12648593" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Clinical parameters and treatment results in recurrent granulosa cell tumor of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15285297" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Clinical review of 63 cases of sex cord stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11860546" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Postoperative chemotherapy in advanced ovarian granulosa cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15589602" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--a multivariate analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28532858" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Ovarian granulosa cell tumor: A National Cancer Database study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29667339" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Adjuvant chemotherapy in patients with operable granulosa cell tumors of the ovary: a surveillance, epidemiology, and end results cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12637488" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Granulosa cell tumor of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11371138" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Granulosa cell tumor of the ovary: a population-based study of 37 women with stage I disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10021290" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9764376" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Granulosa cell tumours of the ovary: demographics, survival and the management of advanced disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2418394" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1690679" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : cis-platinum/vinblastine/bleomycin combination chemotherapy in advanced or recurrent granulosa cell tumors of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22446621" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Ovarian Sertoli-Leydig cell tumors. a retrospective MITO study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8602303" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15337800" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The activity of taxanes in the treatment of sex cord-stromal ovarian tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19191075" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Improvement of survival in sex cord stromal tumors - an observational study with more than 25 years follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19191075" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Improvement of survival in sex cord stromal tumors - an observational study with more than 25 years follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8307501" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Granulosa cell tumors of the ovary: prognostic factors and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21752752" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25808251" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The clinical utility of serum anti-Müllerian hormone in the follow-up of ovarian adult-type granulosa cell tumors--A comparative study with inhibin B.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23623833" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Recurrent granulosa cell tumors (GCTs) of the ovary: a MITO-9 retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27174627" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Maximum surgical effort is warranted for recurrent adult granulosa cell tumors of ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10094877" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2532171" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Gonadotropin-releasing hormone agonist analog therapy effective in ovarian granulosa cell malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8799913" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19574768" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Promising effect of aromatase inhibitors on recurrent granulosa cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22136798" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24166194" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11578471" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Recurrent ovarian granulosa cell tumor: a case report of a dramatic response to Taxol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15863149" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11277661" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Management of recurrent juvenile granulosa cell tumor of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26616224" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/703991" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : A temporary response of recurrent granulosa cell tumor to adriamycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9038278" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Management of advanced juvenile granulosa cell tumor of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7705666" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Clinical review of adult granulosa cell tumors of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2245809" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Recurrent ovarian granulosa cell tumor: role of combination chemotherapy with report of a long-term response to a cyclophosphamide, doxorubicin and cisplatin regimen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3658288" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1390308" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Cisplatin-containing regimen in advanced or recurrent granulosa cell tumours of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7962452" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9332694" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Megestrol activity in recurrent adult type granulosa cell tumour of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15721440" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8208521" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Failure of gonadotropin releasing hormone therapy in patients with metastatic ovarian sex cord stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24713548" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Hormone therapy in ovarian granulosa cell tumors: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19524286" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31116423" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : The current state of molecular testing in the treatment of patients with solid tumors, 2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34238613" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9061323" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Platinum based chemotherapy to treat recurrent Sertoli-Leydig cell ovarian carcinoma during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7574820" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : [A case of ovarian malignant Sertoli-Leidig cell tumor treated with CBDCA, etoposide and epirubicin chemotherapy].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2413037" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Hemolytic uremic syndrome in a patient on cis-platinum, vinblastine and bleomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9988794" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Review of the granulosa-theca cell tumors from the emil Novak ovarian tumor registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14528083" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Granulosa cell tumor of the ovary: retrospective analysis of 45 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17868338" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Characteristics of recurrence in adult-type granulosa cell tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9299263" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Prognostic significance of p53 expression in ovarian granulosa cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7705680" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Granulosa cell tumor of ovary: a clinicopathologic and flow cytometric DNA analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15589608" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Long natural history of recurrent granulosa cell tumor of the ovary 23 years after initial diagnosis: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11516814" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Vascular endothelial growth factor levels in pleural and peritoneal fluid in Meigs' syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22850410" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
